Similarly, the search for TILs in tissue samples from metastatic NSCLC or melanoma patients treated with anti-PD1 drugs highlighted that response rates increased with CD8+ lymphocyte count and CD8+/CD4+ ratios [135]. This evidence concerns the gene CD8A and melanoma.